Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by KalVista Pharmaceuticals, Inc.
< Previous
1
2
3
4
Next >
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
May 24, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
May 21, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
May 01, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
April 22, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
March 18, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
March 12, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
March 11, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
March 08, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
March 07, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
March 06, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 27, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 26, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
February 20, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 16, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
February 15, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
February 14, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
February 13, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology
December 20, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
December 07, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
November 14, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved
November 13, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
November 07, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
November 02, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALV
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.